Adj. EBITA slightly below expectations Continued strong organic growth of 44% Solid outlook with con...
Etteplan announced a recommended cash offer for Swedish technology company Semcon.
Redeye will likely make forecast adjustments following Penneo’s Q2’22 report, showing slightly lower...
Redeye sees a report that showed considerably stronger sales development in the quarter than expecte...
Redeye is encouraged by M.O.B.A. Network’s Q2’22 report.
No material updates, presentation today at 10:00 CET Cash at SEK 322.
Redeye leaves its comments on Calmark following its Q2 report.
Redeye makes minor forecast adjustments following Binero’s Q2’22 report.
23% organic sales growth Demand remains strong in Q3, margins to improve 7x ’23e EV/EBITA Sales up 1...
Redeye comments on today’s Q2 report from Annexin Pharmaceuticals and largely reiterate our view of ...
Good Q2 report, we raise our ’22-‘23e EBITDA New product launches to drive higher growth in H2 ~0.
Redeye comments on Isofol’s Q2 2022 report, roughly three weeks after the company communicated that ...
Fluicell offers innovative R&D instruments for single-cell analysis and 3D bioprinting, a business a...
Sales and adj. EBITA 20% and 12% vs. ABGSCe Organic growth of 23% vs.
Redeye was hoping for a little more in terms of top-line growth.
Etteplan offers SEK 149 per share Has the backing of ~47% of current shareholders Acceptance perio...
LL Lucky Games AB (”LL Lucky Games" eller "Bolaget”) visade lägre intäkter än väntat under Q2-22, dä...
Alltainer AB (”Alltainer” eller ”Bolaget”) presenterade nyligen sin Q4-rapport, vilken i sig inte in...
Carlsquare Equity Research har gjort en analysuppdatering på Spotlight Group efter bolagets kvartals...
Etteplan announced a recommended cash offer of SEK 149 per Semcon’s share, for a total value of appr...
